Skip to content
ClinCalc Pro
Menu
First-generation cephalosporin

Cefradine

Brand names: Velosef (legacy)

Cefradine is a first-generation cephalosporin antibacterial used for susceptible infections of the skin and soft tissue, respiratory tract and urinary tract.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a beta-lactam that binds penicillin-binding proteins to inhibit bacterial cell-wall synthesis, giving a bactericidal effect with good activity against many Gram-positive organisms.

Prescribing in practice

  • Avoid in patients with a history of immediate hypersensitivity to penicillins or other beta-lactams because of the risk of cross-reactivity.
  • As a first-generation agent it has limited Gram-negative cover, so it is not suitable for many resistant or hospital-acquired infections.
  • Dose adjustment is required in significant renal impairment, in line with the SPC.

Monitoring

Routine monitoring is not generally needed for short courses, but renal function should guide dosing and clinical response should be reviewed.

Counselling the patient

  • Complete the full prescribed course even if you feel better.
  • Report any rash, swelling, breathing difficulty, or severe or persistent diarrhoea.

Evidence & guidelines

Use is supported by standard UK prescribing references for susceptible infections rather than by a specific landmark trial.

Reference: BSAC; UKHSA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.